Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
adjuvant
Biotech
Merck, Moderna sustain 49% melanoma risk reduction at 5 years
The continued reduction in the risk of cancer recurrence or death boosted the companies’ prospects as they close in on phase 3 data.
Nick Paul Taylor
Jan 20, 2026 8:50am
Roche links SERD to 30% breast cancer risk reduction in phase 3
Dec 10, 2025 8:15am
'Active' vaccine adjuvant boosts COVID, flu antibodies in mice
Jul 9, 2024 4:00am
CureVac rethinks lead cancer program after posting PD-1 data
Nov 16, 2022 8:30am
Novavax BA.1 booster data support COVID-19 vaccine strain switch
Nov 8, 2022 9:40am
Clover's COVID-19 vaccine tames delta in pivotal study
Sep 22, 2021 8:55am
